View live charts, options flow & technicals for IDEXX Laboratories, Inc. →
Open Dashboard
IDEXX Laboratories, Inc. (IDXX) is a healthcare company in the diagnostics & research industry with $4.55B in trailing revenue trading at a 37.0× trailing P/E — analyst consensus: buy.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Key Statistics
Market Cap
$40.91B
Revenue (TTM)
$4.55B
EPS (TTM)
$14.02
EPS (Fwd est.)
$16.74
Employees
11,000
Trailing P/E
37.04
Forward P/E
31.02
PEG Ratio
2.81
Price / Sales
8.98
Price / Book
25.40
EV / EBITDA
25.78
Beta (5Y)
1.54
Analyst Consensus
Consensus
Buy
Analyst Price Target
+35.1% upside
Target: $701.33
Annual Revenue & Net Income
RevenueNet Income
'22
$3.37B
$680.00M
'23
$3.66B
$850.00M
'24
$3.90B
$890.00M
'25
$4.30B
$1.06B
Earnings History
Quarter
Actual EPS
Estimate
Result
Aug 2026
$4.27
$3.93
Beat (+8.5%)
May 2026
$3.47
$3.41
Beat (+1.7%)
Feb 2026
$3.08
$2.94
Beat (+4.8%)
Nov 2025
$3.40
$3.15
Beat (+8.1%)
Next Earnings Report
IDEXX Laboratories, Inc. is next expected to report earnings on 02 Nov 2026.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine…
What is IDXX's market cap?
IDEXX Laboratories, Inc. has a market capitalization of approximately $40.91B.
What is IDXX's P/E ratio?
IDEXX Laboratories, Inc. trades at a trailing P/E ratio of 37.0x and a forward P/E of 31.0x, which is above the broad market average of ~25x.
How much revenue does IDXX generate?
IDEXX Laboratories, Inc. generated $4.55B in trailing 12-month revenue.
What do analysts say about IDXX?
The analyst consensus rating for IDEXX Laboratories, Inc. is buy, with a mean price target of $701.33. That implies +35.1% upside from the current price.
When does IDXX report earnings?
IDEXX Laboratories, Inc. is next scheduled to report earnings on 02 Nov 2026.
Does IDXX pay a dividend?
IDEXX Laboratories, Inc. does not currently pay a regular dividend.
View live charts, options flow, gamma exposure, earnings history, and technical analysis for IDEXX Laboratories, Inc. on Apsis Markets.